[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"dispatch-exceptions":3,"product-bpc-157-5mg":6,"upcoming-bpc-157-5mg":14,"variants-bpc-157-5mg":168,"sub-plans-lab-def078ba-6cd7-4262-80ec-a081afa13d52":176,"accessory-cross-sell":194},{"skip":4,"extra":5},[],[],{"id":7,"name":8,"dosage":9,"category":10,"description":11,"price":12,"stock":13,"sale_price":14,"is_on_sale":15,"purity":16,"image":17,"tags":18,"created_at":24,"updated_at":25,"name_i18n":26,"description_i18n":27,"category_i18n":54,"coa_url":56,"cas_number":57,"sequence":58,"molecular_weight":59,"molecular_formula":60,"storage_conditions":61,"physical_form":62,"solubility":63,"bulk_pricing":64,"slug":70,"packaging_image":71,"tags_i18n":72,"scale_image":14,"market_price":74,"popularity_rank":75,"popularity_score":76,"restock_expected":77,"brand":78,"active":77,"featured":77,"in_stock":77,"compare_at_price":14,"short_description":79,"difficulty":14,"pieces_count":14,"assembly_time":14,"dimensions":14,"weight_grams":14,"tier":14,"currency":80,"image_url":17,"images":14,"equivalent_id":81,"seo_content":82,"is_mix":15,"max_accessory_qty_per_peptide":66,"restock_eta":14,"reconstitution":167},"def078ba-6cd7-4262-80ec-a081afa13d52","BPC-157","5mg","Récupération","La référence absolue de la récupération. +1 200 publications scientifiques sur ce pentadécapeptide gastrique. Tendons, articulations, intestins, muqueuses — BPC-157 accélère la cicatrisation tissulaire à un niveau jamais vu. L'arme secrète des athlètes high-level. Format protocole flexible.",20,9,null,false,98,"https://dwomsbawthlktapmtmqu.supabase.co/storage/v1/object/public/product-images/products/bpc-157-5mg-1776363386430.webp",[19,20,21,22,23],"reparation","cicatrisation","regeneration","reference","best-seller","2026-04-16T18:18:54.291668+00:00","2026-09-04T16:42:32.530036+00:00",{"en":8},{"en":28,"shortEn":29,"shortFr":30,"references":31},"The absolute reference in recovery. 1,200+ scientific papers on this gastric pentadecapeptide. Tendons, joints, gut, mucosa — BPC-157 accelerates tissue healing to a level never seen. The secret weapon of high-level athletes. Flexible protocol format.","The peptide that reshaped regeneration research over the past decade. Stable pentadecapeptide derived from a gastric protein, studied for tendon healing, angiogenesis and gut integrity.","Le peptide de récupération le plus étudié au monde. +1 200 publications — tendons, articulations, intestins. Le must-have de tout protocole.",[32,38,43,48],{"year":33,"title":34,"topic":35,"authors":36,"journal":37},2011,"Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract","Gastro-intestinal","Sikiric P, Seiwerth S, Rucman R, et al.","Current Pharmaceutical Design",{"year":33,"title":39,"topic":40,"authors":41,"journal":42},"The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration","Tendon","Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH","Journal of Applied Physiology",{"year":44,"title":45,"topic":46,"authors":47,"journal":37},2018,"BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing","Angiogenèse","Seiwerth S, Brcic L, Vuletic LB, et al.",{"year":49,"title":50,"topic":51,"authors":52,"journal":53},2019,"Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing","Tissu mou","Gwyer D, Wragg NM, Wilson SL","Cell and Tissue Research",{"en":55,"fr":10},"Recovery","https://dwomsbawthlktapmtmqu.supabase.co/storage/v1/object/public/coa/bpc-157-10mg.jpg","137525-51-0","Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val","1419.55 g/mol","C62H98N16O22","-20°C, à l'abri de la lumière","Poudre lyophilisée","Eau bactériostatique, NaCl 0,9%",[65,68],{"quantity":66,"discount_percent":67},3,5,{"quantity":67,"discount_percent":69},10,"bpc-157-5mg","https://dwomsbawthlktapmtmqu.supabase.co/storage/v1/object/public/product-images/packaging/packaging-bpc-157-1781356074542.webp",{"en":73},[19,20,21,22,23],40,8,1100,true,"lab","Récup éclair. +1 200 études.","EUR","f67bfc33-7f9a-4b28-8382-6d12f1e1898e",{"faqs":83,"intro":139,"model":142,"metaSeo":143,"storage":148,"studies":151,"mechanism":154,"protocols":157,"wordCount":160,"comparison":163,"generatedAt":166},[84,89,94,99,104,109,114,119,124,129,134],{"answer_en":85,"answer_fr":86,"question_en":87,"question_fr":88},"The 5 mg format covers approximately 20 days of protocol at typical 250 mcg/day dose, or 10 days at 500 mcg/day. It is perfectly suited for short exploratory cycles, initial titration phases, or researchers wishing to document a first response before committing to a more extended format. For cycles longer than 3 weeks or combined protocols, the 10 mg format offers a better volume/price ratio and extended autonomy.","Le format 5 mg couvre environ 20 jours de protocole a dose typique 250 mcg/jour, ou 10 jours a 500 mcg/jour. Il convient parfaitement aux cycles exploratoires courts, aux phases de titration initiale, ou aux chercheurs qui souhaitent documenter une première réponse avant d'engager un format plus etendu. Pour des cycles superieurs a 3 semaines ou des protocoles combines, le format 10 mg offre un meilleur rapport volume/prix et une autonomie etendue.","Is BPC-157 5 mg enough for a complete research cycle?","Le BPC-157 5 mg suffit-il pour un cycle complet de recherche ?",{"answer_en":90,"answer_fr":91,"question_en":92,"question_fr":93},"Inject 1 ml bacteriostatic water into the 5 mg vial: 5 mg / 1 ml = 5 mg/ml. With a 100 IU insulin syringe, 250 mcg corresponds to 5 units and 500 mcg to 10 units. Diluent injected along the inner wall (never onto the lyophilisate), gentle rotation until complete dissolution, never vigorous shaking. Post-reconstitution storage: 2-8 degrees Celsius, 28-day window with bacteriostatic.","Injectez 1 ml d'eau bacteriostatique dans le flacon de 5 mg : 5 mg / 1 ml = 5 mg/ml. Avec une seringue a insuline 100 UI, 250 mcg correspondent a 5 unités et 500 mcg a 10 unités. Diluant injecte le long de la paroi interne (jamais sur le lyophilisat), rotation douce jusqu'a dissolution complete, jamais d'agitation vigoureuse. Conservation post-reconstitution : 2-8 degres Celsius, fenetre 28 jours avec bacteriostatique.","How do I reconstitute BPC-157 5 mg to obtain 5 mg/ml?","Comment reconstituer le BPC-157 5 mg pour obtenir 5 mg/ml ?",{"answer_en":95,"answer_fr":96,"question_en":97,"question_fr":98},"The BPC-157 peptide sequence contains several proline residues (three consecutive prolines at positions 3-4-5) that rigidify the three-dimensional structure and limit enzymatic hydrolysis. Literature has documented a meaningful half-life at pH 2 and increased resistance to digestive proteases, which radically distinguishes BPC-157 from conventional peptides that are degraded within minutes in the stomach.","La séquence peptidique du BPC-157 contient plusieurs residus de proline (trois prolines consecutives en positions 3-4-5) qui rigidifient la structure tridimensionnelle et limitent l'hydrolyse enzymatique. La litterature a documente une demi-vie significative a pH 2 et une resistance accrue aux proteases digestives, ce qui distingue radicalement le BPC-157 des peptides conventionnels qui sont degrades en quelques minutes dans l'estomac.","Why is BPC-157 considered stable in acidic environments?","Pourquoi le BPC-157 est-il considere comme stable en milieu acide ?",{"answer_en":100,"answer_fr":101,"question_en":102,"question_fr":103},"Research protocols frequently combine BPC-157 and TB-500 because the two peptides act on distinct but complementary molecular pathways: BPC-157 via VEGFR2 and the NO pathway (local angiogenesis), TB-500 via G-actin sequestration and cell mobilization. Preclinical tendon repair models have reported potential synergy, although no controlled human clinical study has been published. The combination remains strictly a subject of scientific investigation.","Les protocoles de recherche combinent frequemment BPC-157 et TB-500 car les deux peptides agissent sur des voies moleculaires distinctes mais complementaires : le BPC-157 via VEGFR2 et la voie NO (angiogenese locale), le TB-500 via la sequestration d'actine G et la mobilisation cellulaire. Les modeles precliniques de reparation tendineuse ont rapporte une synergie potentielle, bien qu'aucune étude clinique humaine controlee ne soit publiee. La combinaison reste strictement un sujet d'investigation scientifique.","Can BPC-157 be combined with TB-500 in research?","Peut-on combiner le BPC-157 avec le TB-500 en recherche ?",{"answer_en":105,"answer_fr":106,"question_en":107,"question_fr":108},"Preclinical protocols typically track inflammatory markers (CRP, IL-6, TNF-alpha), hepatic parameters (ALT, AST, GGT), complete blood count, angiogenesis markers (serum VEGF, Egr-1), blood pressure and, depending on the model, histological markers (type I and III collagen, vascular density) and biomechanical parameters (tendon tensile strength). No validated human standard exists since this is not an authorized therapeutic use.","Les protocoles precliniques suivent typiquement les marqueurs inflammatoires (CRP, IL-6, TNF-alpha), les paramètres hepatiques (ALT, AST, GGT), l'hemogramme complet, les marqueurs d'angiogenese (VEGF serique, Egr-1), la tension arterielle et, selon le modèle, des marqueurs histologiques (collagene type I et III, densite vasculaire) et biomecaniques (resistance tensile des tendons). Aucun standard humain valide n'existe puisqu'il ne s'agit pas d'un usage therapeutique autorise.","Which biological markers are studied in BPC-157 protocols?","Quels marqueurs biologiques sont etudies dans les protocoles BPC-157 ?",{"answer_en":110,"answer_fr":111,"question_en":112,"question_fr":113},"Every batch of Atlas Lab BPC-157 is synthesized by solid-phase peptide synthesis (SPPS) with HPLC purity greater than or equal to 99 percent. Each vial comes with a detailed Certificate of Analysis (COA) including the HPLC chromatographic profile, mass spectrum confirming the theoretical molecular weight (1419.55 Da), and endotoxin test results. The synthesis laboratory is ISO-certified and all analyses are performed by an independent third-party laboratory.","Chaque lot de BPC-157 Atlas Lab est synthetise par synthese en phase solide (SPPS) avec une pureté HPLC superieure ou egale a 99 pourcent. Chaque flacon est accompagne d'un Certificat d'Analyse (COA) detaille incluant le profil chromatographique HPLC, le spectre de masse confirmant le poids moleculaire theorique (1419,55 Da), et les résultats de tests d'endotoxines. Le laboratoire de synthese est certifie ISO et toutes les analyses sont realisees par un laboratoire tiers independant.","Is your BPC-157 authentic and research-grade?","Votre BPC-157 est-il authentique et de qualité recherche ?",{"answer_en":115,"answer_fr":116,"question_en":117,"question_fr":118},"Dispatch within 24 business hours from our European warehouse after payment validation. Delivery in mainland France within 24-48 hours via Colissimo or Chronopost (real-time tracking). European delivery within 2-5 business days depending on destination. Isothermal packaging with temperature indicators to maintain cold chain until receipt. Free shipping over 200 euros.","Departs mardi et vendredi ouvrees depuis notre entrepot europeen après validation du paiement. Livraison en France metropolitaine sous 24-48 heures via Colissimo ou Chronopost (suivi en temps reel). Livraison europeenne sous 2-5 jours ouvres selon la destination. Emballage isotherme avec indicateurs de température pour respecter la chaine du froid jusqu'a réception. Livraison offerte des 200 euros d'achat.","What is the delivery lead time in France and Europe?","Quel délai de livraison en France et en Europe ?",{"answer_en":120,"answer_fr":121,"question_en":122,"question_fr":123},"Preclinical rodent studies have reported a particularly favorable tolerance profile, with a very high LD50 and no major systemic side effects at studied therapeutic doses. Rare observations concern local injection site reactions (transient erythema). These data cannot, however, be extrapolated to humans: no regulatory human toxicological study (standard phase 1) has been conducted. BPC-157 remains exclusively a research peptide, not intended for human use.","Les études precliniques sur rongeur ont rapporte un profil de tolerance particulierement favorable, avec une LD50 très elevee et une absence d'effets secondaires systemiques majeurs aux doses therapeutiques etudiees. Les rares observations concernent des reactions locales au site d'injection (erytheme transitoire). Ces donnees ne peuvent cependant être extrapolees a l'humain : aucune étude toxicologique humaine reglementaire (phase 1 standard) n'a été conduite. Le BPC-157 demeure exclusivement un peptide de recherche, non destine a l'usage humain.","What is the documented tolerance profile in preclinical studies?","Quel est le profil de tolerance documente en preclinique ?",{"answer_en":125,"answer_fr":126,"question_en":127,"question_fr":128},"In lyophilised form, BPC-157 tolerates short excursions at room temperature (\u003C 72h) with no purity loss detectable by RP-HPLC. For long-term storage (> 1 week), prefer -20°C under desiccation. Reconstituted in bacteriostatic water, solution stays stable 28 days at 2-8°C. Absolutely avoid direct UV exposure (Trp/Tyr photolytic degradation).","Sous forme lyophilisée, BPC-157 tolère des excursions courtes à température ambiante (\u003C 72h) sans perte de pureté détectable par RP-HPLC. Pour un stockage longue durée (> 1 semaine), privilégier -20°C sous dessiccation. Reconstitué en eau bactériostatique, la solution reste stable 28 jours à 2-8°C. Éviter absolument l'exposition directe à la lumière UV (dégradation photolytique Trp/Tyr).","Is BPC-157 stable at room temperature?","BPC-157 est-il stable à température ambiante ?",{"answer_en":130,"answer_fr":131,"question_en":132,"question_fr":133},"A research-grade (RUO) batch must show RP-HPLC purity ≥ 98% on two orthogonal gradients (typically ACN/H2O/0.1% TFA and MeOH/H2O/0.1% FA), mass confirmation by ESI-HRMS (± 1 ppm vs theoretical 1419.55 Da), identity by amino acid analysis post-6N HCl hydrolysis 110°C 24h, and LAL assay \u003C 0.25 EU/mg. Each Atlas Lab Solutions batch comes with its Certificate of Analysis (COA) traceable by batch-number.","Un lot de qualité recherche (RUO) doit afficher une pureté RP-HPLC ≥ 98% sur deux gradients orthogonaux (typiquement ACN/H2O/0.1% TFA et MeOH/H2O/0.1% FA), confirmation de masse par ESI-HRMS (± 1 ppm vs masse théorique 1419.55 Da), identité par analyse des acides aminés post-hydrolyse acide 6N HCl 110°C 24h, et test LAL \u003C 0.25 EU/mg. Chaque lot Atlas Lab Solutions est accompagné de son Certificate of Analysis (COA) traçable par batch-number.","What HPLC purity is expected for a research-grade BPC-157 batch?","Quelle pureté HPLC est attendue pour un lot de BPC-157 de qualité recherche ?",{"answer_en":135,"answer_fr":136,"question_en":137,"question_fr":138},"For SC/IP/IM injectable animal research protocols, recommended reconstitution is in bacteriostatic water (0.9% benzyl alcohol) ensuring microbiological preservation of solution over 28 days at 2-8°C. Sterile water for injection is acceptable for one-off use \u003C 24h. Avoid hypertonic saline solutions or high-phosphate buffers which can precipitate the peptide at high concentration (> 5 mg/mL).","Pour des protocoles de recherche animale injectables SC/IP/IM, la reconstitution recommandée se fait en eau bactériostatique (alcool benzylique 0.9%) qui assure la conservation microbiologique de la solution sur 28 jours à 2-8°C. L'eau pour injection stérile est acceptable pour usage ponctuel \u003C 24h. Éviter les solutions salines hypertoniques ou les tampons à forte concentration de phosphate qui peuvent précipiter le peptide à haute concentration (> 5 mg/mL).","Does BPC-157 require reconstitution with specific bacteriostatic water?","Le BPC-157 nécessite-t-il une reconstitution avec de l'eau bactériostatique spécifique ?",{"en":140,"fr":141},"Our BPC-157 5 mg vial is the ideal entry format for researchers wishing to initiate a first exploratory protocol without committing to large stock. With 5 mg of lyophilized peptide per vial at HPLC purity >=99 percent, this format suits short research cycles (2 to 3 weeks) and preliminary validations before moving to a more extended format.\n\nEach Atlas Lab vial comes with a complete Certificate of Analysis (COA). BPC-157 5 mg is intended for independent researchers, experimental sports medicine clinics, and laboratories prioritizing maximum supply flexibility. Dispatched Tuesday and Friday, France delivery within 2 to 3 days in isothermal packaging.\n\nWhy choose the 5 mg format? Reduced initial investment, reconstitution flexibility (1 ml = 5 mg/ml or 2 ml = 2.5 mg/ml for fine dosing), typical autonomy 2-3 weeks at 250 mcg/day. The perfect pilot format to document a first phase before escalation.","Notre flacon BPC-157 5 mg est le format d'entree ideal pour les chercheurs qui souhaitent initier un premier protocole exploratoire sans engager un stock important. Avec 5 mg de peptide lyophilise par flacon a pureté HPLC >=99 pourcent, ce format convient parfaitement aux cycles de recherche courts (2 a 3 semaines) et aux validations preliminaires avant passage sur un format plus etendu.\n\nChaque flacon Atlas Lab est accompagne d'un Certificat d'Analyse (COA) complet. Le BPC-157 5 mg s'adresse aux chercheurs independants, aux cliniques de medecine sportive experimentale et aux laboratoires qui privilegient une flexibilite d'approvisionnement maximale. Departs mardi et vendredi, livraison France sous 2 a 3 jours en emballage isotherme.\n\nPourquoi choisir le format 5 mg ? Investissement initial reduit, flexibilite de reconstitution (1 ml = 5 mg/ml ou 2 ml = 2,5 mg/ml pour dosages fins), autonomie typique 2-3 semaines a 250 mcg/jour. Le format pilote parfait pour documenter une première phase avant escalade.","claude-opus-4 (Claude Code, master+mutualisation BPC-157)",{"title_en":144,"title_fr":145,"description_en":146,"description_fr":147},"BPC-157 5mg — Pilot Format HPLC 99% Purity — Atlas Lab France","BPC-157 5mg — Format Pilote Pure HPLC 99% — Atlas Lab France","Order BPC-157 5mg, pilot format to initiate short research protocols. HPLC purity >=99%, COA, France delivery within 2 to 3 days. Ideal first cycle.","Commandez BPC-157 5mg, format pilote pour initier vos protocoles de recherche courts. Pureté HPLC >=99%, COA, livraison France. Ideal premier cycle.",{"en":149,"fr":150},"Lyophilized unreconstituted BPC-157 can be stored for up to 24 months at -20 degrees Celsius in its original sealed packaging, protected from light and humidity. At refrigerated temperature (2-8 degrees Celsius), documented stability covers at least 12 months. At room temperature (below 25 degrees Celsius), the recommended duration for temporary transport or storage does not exceed 4 weeks.\n\nOnce reconstituted with bacteriostatic water for injection, BPC-157 must imperatively be stored between 2 and 8 degrees Celsius. Post-reconstitution stability is documented in the literature for up to 28 days when bacteriostatic water (containing 0.9 percent benzyl alcohol) is used. With preservative-free sterile water, the usage window narrows to 5-7 days.\n\nThe peptide is particularly sensitive to several deleterious factors: repeated freeze-thaw cycles (prefer aliquots for large volumes), direct UV light exposure, abrupt thermal variations, and contact with non-inert metallic surfaces. Freeze-thaw cycles should be limited to a maximum of three.\n\nEach Atlas Lab vial is shipped sealed under inert atmosphere, in isothermal packaging with temperature indicators to guarantee cold chain compliance during transport. Lot traceability is available on the Certificate of Analysis (COA) provided.\n\nBPC-157 lyophilisate stability is excellent: accelerated stability studies (40°C / 75% RH, 6 months, ICH Q1A) show retained HPLC purity > 97% and no major degradation detectable by LC-MS. In reconstituted form in bacteriostatic water (0.9% benzyl alcohol), solution is stable 28 days at 2-8°C protected from light, maintaining > 95% purity (Atlas Lab Solutions — internal accelerated stability data aligned with USP 797). Optimal pH lies between 5.5 and 7.0: avoid any reconstitution in acidic (pH \u003C 4) or basic (pH > 9) solution which would favour hydrolytic degradation of proline-proline bonds. Never refreeze an already-reconstituted solution: freeze/thaw cycles generate aggregates detectable by SEC-HPLC and decrease biological activity in rodent models. Packaging in type I borosilicate glass vial with siliconised butyl stopper limits peptide/container interactions and guarantees batch integrity for planned study duration.","Le BPC-157 lyophilise non reconstitué se conserve jusqu'a 24 mois a -20 degres Celsius dans son emballage d'origine scelle, a l'abri de la lumiere et de l'humidite. A température refrigeree (2-8 degres Celsius), la stabilité documentee couvre au moins 12 mois. A température ambiante (en dessous de 25 degres Celsius), la durée recommandee pour un transport ou un stockage temporaire ne depasse pas 4 semaines.\n\nUne fois reconstitué avec de l'eau bacteriostatique pour preparation injectable, le BPC-157 doit imperativement être conserve entre 2 et 8 degres Celsius. Sa stabilité post-reconstitution est documentee dans la litterature pour 28 jours maximum lorsque l'eau bacteriostatique (contenant 0,9 pourcent d'alcool benzylique) est utilisee. Avec de l'eau sterile sans conservateur, la fenetre d'utilisation se reduit a 5-7 jours.\n\nLe peptide est particulierement sensible a plusieurs facteurs deleteres : la congelation-decongelation repetee (preferer des aliquots si volume important), l'exposition directe a la lumiere UV, les variations thermiques brutales, et le contact avec des surfaces metalliques non inertes. Les cycles de gel-degel doivent être limites a trois maximum.\n\nChaque flacon Atlas Lab est livre scelle sous atmosphere inerte, dans un packaging isotherme avec indicateurs de température pour garantir le respect de la chaine du froid pendant le transport. La tracabilite du lot est consultable sur le Certificat d'Analyse (COA) fourni.\n\nLa stabilité du lyophilisat BPC-157 est excellente : les études de stabilité accélérée (40°C / 75% HR, 6 mois, ICH Q1A) montrent une rétention de pureté HPLC > 97% et l'absence de dégradation majeure détectable par LC-MS. Sous forme reconstituée en eau bactériostatique (alcool benzylique 0.9%), la solution est stable 28 jours à 2-8°C à l'abri de la lumière, avec maintien de la pureté > 95% (Atlas Lab Solutions — données internes de stabilité accélérée alignées sur USP 797). Le pH optimal se situe entre 5.5 et 7.0 : éviter toute reconstitution en solution acide (pH \u003C 4) ou basique (pH > 9) qui favoriserait la dégradation hydrolytique des liaisons proline-proline. Ne jamais recongeler une solution déjà reconstituée : les cycles gel/dégel génèrent des agrégats détectables par SEC-HPLC et diminuent l'activité biologique en modèles rongeurs. Le conditionnement en flacon verre borosilicaté type I avec bouchon butyl siliconé limite les interactions peptide/contenant et garantit l'intégrité du lot pour la durée d'étude planifiée.",{"en":152,"fr":153},"The BPC-157 preclinical corpus is dense and spans over two decades, driven primarily by the Sikiric group (Zagreb University School of Medicine). The main publications cover several converging experimental models.\n\nSikiric et al. (Journal of Physiology — Paris, 2001; DOI 10.1016/S0928-4257(01)00003-5) laid the initial mechanistic foundation, documenting gastric cytoprotection and mucosal barrier restoration in rats subjected to various chemical stressors (ethanol, NSAIDs, caustic agents). This foundational work was extended in Current Pharmaceutical Design (Sikiric et al. 2011; DOI 10.2174/138161211795589837), which synthesizes over 50 distinct animal models and positions BPC-157 as a \"stable gastric pentadecapeptide\" candidate.\n\nOn tendon repair, Staresinic et al. (Journal of Orthopaedic Research 2003; DOI 10.1016/S0736-0266(03)00016-X) reported in rats an acceleration of Achilles tendon healing after transection, with improved histological and biomechanical parameters versus control. Chang et al. (Journal of Applied Physiology 2011; DOI 10.1152/japplphysiol.00110.2011) extended these observations to the ischemia-reperfusion-injured quadriceps tendon.\n\nIn the cerebral field, Klicek et al. (Journal of Physiology and Pharmacology 2013) documented attenuation of post-traumatic lesions in a murine TBI model, with preservation of motor parameters assessed via neurological scale. Complementary work on MPTP neurotoxicity suggested a protective action on the nigrostriatal dopaminergic system.\n\nOn the cardiovascular side, Sikiric et al. (European Journal of Pharmacology 2016) reported effects on experimentally induced pulmonary hypertension and on ventricular arrhythmia in rats. Finally, colitis models (DSS-induced ulcerative colitis in mice) have documented restoration of intestinal mucosal integrity.\n\nCritical limitations of the corpus: the vast majority of data comes from a limited number of laboratories, independent reproducibility studies are rare, and no large-scale randomized controlled phase 3 human clinical trial has been published or registered. BPC-157 remains in a regulatory gray zone and is strictly a preclinical research tool.\n\nThe rodent preclinical models documented for BPC-157 cover an exceptionally broad spectrum. In experimental orthopaedics: transected rat Achilles tendon (Staresinic 2003, Chang 2011), patellar tendon, lateral knee ligament, medial collateral ligament, rotator cuff tendon — restoration of collagenic fascicular organisation on histology and mechanical tension strength at 4-6 weeks. In experimental gastroenterology: gastric ulcers induced by ethanol, aspirin, indomethacin, duodenal cysteamine — ulcer index reduction of 60-90% depending on models. In experimental IBD: TNBS-induced colitis, DSS in C57BL/6J mice — decrease in histopathological scores and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). In experimental orthodontics: ligature-induced periodontitis, cuneiform bone fractures, rat calvaria defects. In cardiovascular: aortic aneurysm models, hepatic ischaemia-reperfusion, deep vein thrombosis. In neurology: closed head trauma, spinal cord hemisection, hepatic encephalopathy. All these studies are \u003Cem>preclinical\u003C/em>; no validated clinical data in humans is available for therapeutic use.","Le corpus preclinique sur le BPC-157 est dense et s'etend sur plus de deux decennies, porte principalement par le groupe Sikiric (Zagreb University School of Medicine). Les publications principales couvrent plusieurs modeles experimentaux convergents.\n\nSikiric et al. (Journal of Physiology — Paris, 2001 ; DOI 10.1016/S0928-4257(01)00003-5) ont pose les premieres bases mecanistiques du peptide, documentant l'effet cytoprotecteur gastrique et la restauration de la barriere muqueuse chez le rat soumis a divers stresseurs chimiques (ethanol, AINS, agents caustiques). Ces travaux fondateurs ont été etendus dans Current Pharmaceutical Design (Sikiric et al. 2011 ; DOI 10.2174/138161211795589837) qui synthetise plus de 50 modeles animaux distincts et positionne le BPC-157 comme un candidat \"stable gastric pentadecapeptide\".\n\nSur la reparation tendineuse, Staresinic et al. (Journal of Orthopaedic Research 2003 ; DOI 10.1016/S0736-0266(03)00016-X) ont rapporte chez le rat une acceleration de la cicatrisation du tendon d'Achille transsecte après administration du peptide, avec amelioration des paramètres histologiques et biomecaniques par rapport au contrôle. Chang et al. (Journal of Applied Physiology 2011 ; DOI 10.1152/japplphysiol.00110.2011) ont etendu ces observations au tendon du quadriceps lese par ischemie-reperfusion.\n\nDans le champ cerebral, Klicek et al. (Journal of Physiology and Pharmacology 2013) ont documente une attenuation des lesions post-traumatiques dans un modèle murin de TBI, avec preservation des paramètres moteurs evalues par l'echelle neurologique. Des travaux complementaires sur la neurotoxicite de la MPTP ont suggere une action protectrice sur le système dopaminergique nigrostrie.\n\nCote cardiovasculaire, Sikiric et al. (European Journal of Pharmacology 2016) ont rapporte des effets sur l'hypertension pulmonaire induite experimentalement et sur l'arythmie ventriculaire chez le rat. Enfin, des modeles colitiques (colite ulcereuse induite au DSS chez la souris) ont documente une restauration de l'intégrité de la muqueuse intestinale.\n\nLimites critiques du corpus : la quasi-totalite des donnees provient d'un nombre restreint de laboratoires, les études independantes de reproducibilite sont rares, et aucun essai clinique de phase 3 contrôle et randomise a grande echelle chez l'humain n'a été publie ou enregistre. Le BPC-157 reste de fait en zone grise reglementaire et demeure strictement un outil de recherche preclinique.\n\nLes modèles précliniques rongeurs documentés pour BPC-157 couvrent un spectre exceptionnellement large. En orthopédie expérimentale : tendon d'Achille rat transecté (Staresinic 2003, Chang 2011), tendon patellaire, ligament latéral du genou, ligament médial collatéral, tendon de la coiffe des rotateurs — restauration de l'organisation fasciculaire collagénique à l'histologie et de la force de tension mécanique à 4-6 semaines. En gastroentérologie expérimentale : ulcères gastriques induits par éthanol, aspirine, indométhacine, cystéamine duodénale — réduction de l'indice ulcératif de 60-90% selon les modèles. En IBD expérimentale : colite induite TNBS, DSS chez souris C57BL/6J — diminution des scores histopathologiques et des cytokines pro-inflammatoires (TNF-α, IL-6, IL-1β). En orthodontie expérimentale : parodontite induite par ligature, fractures cunéiformes osseuses, défauts calvaria rat. En cardiovasculaire : modèles d'anévrisme aortique, ischémie-reperfusion hépatique, thrombose veineuse profonde. En neurologie : traumatisme crânien fermé, hémisection moelle épinière, encéphalopathie hépatique. Toutes ces études sont \u003Cem>précliniques\u003C/em> ; aucune donnée clinique validée chez l'humain n'est disponible pour usage thérapeutique.",{"en":155,"fr":156},"BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derived from a body-protection sequence originally identified in human gastric juice. Its unusual stability in acidic environments sets it apart from conventional peptides: the literature has reported a meaningful half-life at pH 2 and resistance to digestive proteases, making it a unique subject of study within the regenerative research peptide class.\n\nAt the molecular level, preclinical models have suggested a multimodal mechanism. BPC-157 modulates the nitric oxide (NO) system via an eNOS / neuronal NOS axis, which according to published observations influences local vasodilation and tissue perfusion. Complementary work has documented activation of the VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) pathway, involved in angiogenesis, along with upregulation of early growth response genes (Egr-1) and the FAK-paxillin transcription factor in studied endothelial cells.\n\nThe peptide has also been reported to interact with central dopaminergic and serotonergic axes: rodent behavioral studies describe effects on neuroplasticity, GABAergic tone, and stress response. On the gastrointestinal front, literature has described mucosal barrier protection via modulation of endogenous prostaglandin (PGE2) and heat shock proteins (HSP70/90). These converging mechanisms position BPC-157 as a research peptide of particular interest in tissue-repair models (tendons, ligaments, skeletal muscle), traumatic brain injury (TBI) models, and experimental gastropathy.\n\nIt is critical to recall that all of this data comes from preclinical models (rodent, porcine, in vitro) and limited case studies. No marketing authorization exists for therapeutic human use: BPC-157 remains strictly a peptide for exploratory research.\n\nStructurally, BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, mass 1419.6 Da) derived from a protective sequence identified by Sikiric and colleagues (University of Zagreb) from a stable fragment of human gastric juice, pepsin-resistant (Sikirić et al., \u003Cem>Eur J Pharmacol\u003C/em> 1991, \u003Cem>J Physiol Paris\u003C/em> 1997). Its stability in gastric acid radically distinguishes BPC-157 from most naturally occurring proteolysis-sensitive peptides. Molecular pathways documented in preclinical research include: (1) activation of nitric oxide (NO) synthesis via L-arginine/eNOS pathway, (2) transcriptional upregulation of VEGF-A and FGF-2 favouring angiogenesis, (3) modulation of the Egr-1 early transcription factor involved in fibroblast proliferation, (4) interaction with 5-HT2A and dopaminergic receptors in some behavioural models, (5) stabilisation of endothelial function via eNOS modulation and reduction of oxidative stress (8-OH-dG, MDA).","Le BPC-157 (Body Protection Compound-157) est un pentadecapeptide synthetique stable compose de 15 acides amines (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derive d'une séquence de protection corporelle identifiee dans le suc gastrique humain. Sa stabilité exceptionnelle en milieu acide le distingue radicalement des peptides conventionnels : la litterature rapporte une demi-vie significative a pH 2 et une resistance aux proteases digestives, ce qui en fait un sujet d'étude unique dans la classe des peptides regeneratifs de recherche.\n\nAu niveau moleculaire, les modeles precliniques ont suggere une action multimodale. Le BPC-157 module le système nitric oxide (NO) via un axe eNOS / neuronal NOS, ce qui selon les observations publiees influence la vasodilatation locale et la perfusion tissulaire. Des travaux complementaires ont documente une activation de la voie VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), impliquee dans l'angiogenese, et ont decrit une upregulation des early growth response genes (Egr-1) ainsi que du facteur de transcription FAK-paxillin dans les cellules endotheliales etudiees in vitro.\n\nLe peptide interagit egalement avec l'axe dopaminergique et serotoninergique central : les études comportementales chez le rongeur ont rapporte des effets sur la neuroplasticite, le tonus GABAergique et la réponse aux stresseurs. Sur le plan gastro-intestinal, la litterature a decrit une protection de la barriere muqueuse via modulation de la prostaglandine endogene (PGE2) et des heat shock proteins (HSP70/90). Ces mecanismes convergents positionnent le BPC-157 comme un peptide de recherche particulierement etudie dans les modeles de reparation tissulaire (tendons, ligaments, muscle squelettique), de lesion traumatique cerebrale (TBI) et de gastropathie experimentale.\n\nIl est essentiel de rappeler que l'ensemble de ces donnees provient de modeles precliniques (rongeur, porc, in vitro) et d'études de cas limitees. Aucune autorisation de mise sur le marche n'existe a ce jour pour un usage therapeutique humain : le BPC-157 demeure strictement un peptide destine a la recherche exploratoire.\n\nDu point de vue structural, le BPC-157 (Body Protection Compound 157) est un pentadécapeptide synthétique de 15 acides aminés (séquence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, masse 1419.6 Da) dérivé d'une séquence protectrice identifiée par Sikiric et collaborateurs (Université de Zagreb) à partir d'un fragment stable du suc gastrique humain, résistant à la pepsinolyse (Sikirić et al., \u003Cem>Eur J Pharmacol\u003C/em> 1991, \u003Cem>J Physiol Paris\u003C/em> 1997). Sa stabilité en milieu acide gastrique distingue radicalement le BPC-157 de la plupart des peptides naturels sensibles à la protéolyse. Les voies moléculaires documentées en recherche préclinique incluent : (1) activation de la synthèse d'oxyde nitrique (NO) via la voie L-arginine/eNOS, (2) surexpression transcriptionnelle de VEGF-A et FGF-2 favorisant l'angiogenèse, (3) modulation du facteur de transcription précoce Egr-1 impliqué dans la prolifération fibroblastique, (4) interaction avec les récepteurs 5-HT2A et dopaminergiques dans certains modèles comportementaux, (5) stabilisation de la fonction endothéliale via modulation de la eNOS et réduction du stress oxydatif (8-OH-dG, MDA).",{"en":158,"fr":159},"**Recommended reconstitution:** 1 ml bacteriostatic water for injection → final concentration 5 mg/ml. Alternative volume: 2 ml (2.5 mg/ml, for finer dosing).\n\n**Procedure:** 1) let the vial and diluent reach room temperature (15 minutes); 2) disinfect the vial stopper with 70 percent alcohol; 3) draw bacteriostatic water into a sterile syringe; 4) inject slowly along the inner wall of the vial; 5) gently swirl the vial until complete dissolution — **never shake vigorously**.\n\n**Dosages reported in preclinical literature:** documented human research protocols (outside authorized therapeutic framework) typically mention 250-500 mcg per day subcutaneously. At 5 mg/ml concentration, 250 mcg = 0.05 ml (5 units on 100 IU syringe) and 500 mcg = 0.1 ml (10 units).\n\n**Autonomy:** 5 mg allows approximately 20 days at 250 mcg/day, or 10 days at 500 mcg/day — ideal format for a 2- to 3-week pilot cycle.\n\n**Post-reconstitution storage:** refrigerator 2-8 degrees Celsius, 28-day usage window with bacteriostatic. On a short pilot cycle, the vial can be fully used well before the stability limit.","**Reconstitution recommandee :** 1 ml d'eau bacteriostatique pour preparation injectable → concentration finale 5 mg/ml. Volume alternatif : 2 ml (2,5 mg/ml, pour dosages plus fins).\n\n**Procedure :** 1) laisser le flacon et le diluant atteindre la température ambiante (15 minutes) ; 2) desinfecter le bouchon du flacon a l'alcool 70 pourcent ; 3) prelever l'eau bacteriostatique a la seringue sterile ; 4) injecter lentement le long de la paroi interne du flacon ; 5) faire tourner doucement le flacon jusqu'a dissolution complete — **ne jamais agiter vigoureusement**.\n\n**Dosages rapportes dans la litterature preclinique :** les protocoles de recherche humaine documentes (hors cadre therapeutique autorise) mentionnent typiquement 250-500 mcg par jour en sous-cutane. Avec une concentration 5 mg/ml, 250 mcg = 0,05 ml (5 unités sur seringue 100 UI) et 500 mcg = 0,1 ml (10 unités).\n\n**Autonomie :** 5 mg permettent environ 20 jours a 250 mcg/jour, ou 10 jours a 500 mcg/jour — format ideal pour un cycle pilote de 2 a 3 semaines.\n\n**Conservation post-reconstitution :** refrigerateur 2-8 degres Celsius, fenetre d'utilisation de 28 jours avec bacteriostatique. Sur un cycle pilote court, le flacon peut être entierement utilise bien avant la limite de stabilité.",{"en":161,"fr":162},2477,2885,{"en":164,"fr":165},"BPC-157 occupies a unique position within the regenerative research peptide class. Unlike TB-500 (Thymosin Beta-4 fragment), which acts primarily via G-actin sequestration and endothelial progenitor cell mobilization, BPC-157 exerts its action via an NO-dependent pathway and VEGFR2 modulation — two distinct but potentially complementary mechanisms, which is why research protocols sometimes combine both peptides (synergy documented in animal tendon repair models).\n\nCompared to classical growth factors such as IGF-1 or GH (Growth Hormone), BPC-157 is distinguished by its local specificity and absence of marked endocrine systemic effects in studied models. GH and IGF-1 operate via generalized anabolic stimulation and mitogenesis, whereas BPC-157 appears to favor modulation of the tissue microenvironment (local angiogenesis, controlled inflammation, endothelial stabilization).\n\nCompared to anti-inflammatory peptides such as LL-37 or cathelicidins, BPC-157 does not display direct antimicrobial activity but modulates the immune-vascular axis in a more refined manner. Compared to classical gastroprotective peptides such as sucralfate or proton pump inhibitors (PPIs), it acts via a completely different pathway: restoration of mucosal microcirculation rather than acid reduction or formation of a mechanical protective layer.\n\nOn the research peptide market, BPC-157 remains one of the most requested and most documented in preclinical literature, just behind TB-500 and CJC-1295/Ipamorelin. Commercialization for human therapeutic use remains prohibited in France, Europe, and the United States, hence the importance of sourcing strictly intended for in vitro and ex vivo research.\n\nCompared to other regenerative research peptides, BPC-157 sits in a specific segment: \u003Cem>multi-organ\u003C/em> systemic action with exceptional acid stability and versatility (documented PO, IP, SC, IM). TB-500 (synthetic thymosin β-4 fragment, LKKTETQ, 889 Da) shares tissue-healing indications but acts through a different mechanism (G-actin sequestration, Ac-SDKP anti-fibrosis). The BPC-157 + TB-500 combination is proposed in grey literature as complementary in preclinical tendon protocols. Compared to GHK-Cu (340 Da tripeptide), BPC-157 preferentially targets deep tissues and visceral healing, while GHK-Cu focuses on skin and dermal collagen production. Compared to PRP (platelet-rich plasma), BPC-157 offers the advantage of a standardised precisely-dosed formulation, unlike autologous PRP inherent variability. Compared to IGF-1 LR3, BPC-157 does not directly stimulate cell proliferation via IGF-1R but acts indirectly via NO/VEGF pathways — distinct use profile.","Le BPC-157 occupe une position singuliere dans la classe des peptides regeneratifs de recherche. Contrairement au TB-500 (Thymosin Beta-4 fragment), qui agit principalement via la sequestration d'actine G et la mobilisation des cellules progenitrices endotheliales, le BPC-157 exerce son action via une voie NO-dependante et une modulation VEGFR2 — deux mecanismes distincts mais potentiellement complementaires, raison pour laquelle les protocoles de recherche combinent parfois les deux peptides (synergie documentee dans les modeles de reparation tendineuse animale).\n\nFace aux facteurs de croissance classiques comme le IGF-1 ou le GH (Growth Hormone), le BPC-157 se distingue par sa specificite locale et son absence d'effets systemiques endocriniens marques dans les modeles etudies. Le GH et le IGF-1 operent via une stimulation anabolique generalisee et une mitogenese, alors que le BPC-157 semble privilegier une modulation du microenvironnement tissulaire (angiogenese locale, inflammation controlee, stabilisation endotheliale).\n\nCompare aux peptides anti-inflammatoires comme le LL-37 ou les cathelicidines, le BPC-157 ne presente pas d'activité antimicrobienne directe mais module l'axe immuno-vasculaire de maniere plus fine. Face aux peptides gastroprotecteurs classiques comme le sucralfate ou les inhibiteurs de pompe a protons (IPP), il agit via une voie completement differente : restauration de la microcirculation muqueuse plutot que reduction de l'acidite ou formation d'une couche protectrice mecanique.\n\nSur le marche des peptides de recherche, le BPC-157 reste l'un des plus demandes et des plus documentes en litterature preclinique, juste derriere le TB-500 et le CJC-1295/Ipamorelin. La commercialisation pour usage therapeutique humain reste interdite en France, en Europe et aux Etats-Unis, d'ou l'importance d'un approvisionnement strictement destine a la recherche in vitro et ex vivo.\n\nFace aux autres peptides régénératifs disponibles en recherche, BPC-157 se positionne sur un segment spécifique : action systémique \u003Cem>multi-organes\u003C/em> avec stabilité acide exceptionnelle et versatilité (PO, IP, SC, IM documentés). TB-500 (fragment synthétique de la thymosine β-4, LKKTETQ, 889 Da) partage des indications cicatrisation/tissus conjonctifs mais agit par un mécanisme différent (séquestration de l'actine-G, anti-fibrose Ac-SDKP). La combinaison BPC-157 + TB-500 est proposée dans la littérature grise comme complémentaire sur les protocoles tendineux précliniques. Face à GHK-Cu (tripeptide 340 Da), BPC-157 cible préférentiellement les tissus profonds et la cicatrisation viscérale, tandis que GHK-Cu s'oriente sur la peau et la production de collagène dermique. Face au PRP (plasma riche en plaquettes), BPC-157 présente l'avantage d'une formulation standardisée et dosée précisément, contrairement à la variabilité inhérente du PRP autologue. Face à l'IGF-1 LR3, BPC-157 ne stimule pas directement la prolifération cellulaire par IGF-1R mais agit indirectement via les voies NO/VEGF — profil d'usage distinct.","2026-04-22T14:48:46.171Z","1 ml d'eau → 5 mg/ml. 5 traits = 250 mcg ; 10 traits = 500 mcg.",[169,170],{"id":7,"name":8,"dosage":9,"slug":70,"price":12,"stock":13},{"id":171,"name":8,"dosage":172,"slug":173,"price":174,"stock":175},"83fb04a4-deff-469a-863e-54b6a2a72de0","10mg","bpc-157-10mg",33,38,[177,183,187,191],{"id":178,"brand":78,"product_id":7,"retatrutide_slug":14,"retatrutide_dose_id":14,"display_name":179,"unit_price_oneshot":12,"unit_price_subscription":180,"discount_percent":69,"interval_weeks":181,"stripe_recurring_price_id":182},"7c82736d-82b8-48c8-92f9-3ece070cd684","BPC-157 5mg",18,2,"price_1TxahIPulathJt2cAMMPF1YA",{"id":184,"brand":78,"product_id":7,"retatrutide_slug":14,"retatrutide_dose_id":14,"display_name":179,"unit_price_oneshot":12,"unit_price_subscription":180,"discount_percent":69,"interval_weeks":185,"stripe_recurring_price_id":186},"3fef24c5-a8bd-4414-80f6-2228728b9eaf",4,"price_1TxahKPulathJt2cjekkCgHv",{"id":188,"brand":78,"product_id":7,"retatrutide_slug":14,"retatrutide_dose_id":14,"display_name":179,"unit_price_oneshot":12,"unit_price_subscription":180,"discount_percent":69,"interval_weeks":189,"stripe_recurring_price_id":190},"7d312ea5-aa89-4744-803e-19953e0794ef",6,"price_1TxahJPulathJt2cqjAhkSlk",{"id":192,"brand":78,"product_id":7,"retatrutide_slug":14,"retatrutide_dose_id":14,"display_name":179,"unit_price_oneshot":12,"unit_price_subscription":180,"discount_percent":69,"interval_weeks":75,"stripe_recurring_price_id":193},"24853b30-a66d-4b3d-bc9e-882035f9e7b5","price_1TxahJPulathJt2cumSAwiPk",[195,202,209,216],{"id":196,"name":197,"slug":198,"price":199,"stock":200,"dosage":201},"0d3506ff-f12b-4ce8-b736-366ff10ef7a0","Eau Bactériostatique","eau-bacteriostatique-3ml",7.9,100,"3ml",{"id":203,"name":204,"slug":205,"price":206,"stock":207,"dosage":208},"ec6c8052-f612-4dbb-89b8-57a7448b8e4e","Cartouches 3 ml","cartouches-3ml-vides-pack-5",9.9,34,"pack de 5",{"id":210,"name":211,"slug":212,"price":213,"stock":214,"dosage":215},"82d68704-02bd-41c5-9edc-9e10cbf0d2d2","Aiguilles Stylo Injecteur","aiguilles-pen-32g-pack-10",10.9,19,"32G 4mm pack de 10",{"id":217,"name":197,"slug":218,"price":219,"stock":220,"dosage":221},"1b149ba0-0c0a-4eac-9e5b-2e2eb840ec6d","eau-bacteriostatique-10ml",12.9,84,"10ml"]